Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual homing mechanisms of eosinophils to the sputum; sensitivity to mepolizumab
2016-002014-52Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of mepolizumab in eosinophilic asthma (EA) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Eosinophil lifespan in blood and Eosinophil lifespan in lungs. Started Feb 2017; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2016-002014-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002014-52.